MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Anxiety"

  • 2023 International Congress

    Dynamic assessment of levels of depression and anxiety impairment in Parkinson’s disease

    O. Naimov, R. Matmurodov (Tashkent, Uzbekistan)

    Objective: To dynamic assessment of depression and anxiety disorders in Parkinson's disease. Background: One of the most common nonmotor disturbances in Parkinson's disease (PD) is…
  • 2023 International Congress

    Recruitment of Parkinson’s disease patients with mild-to-moderate anxiety into a randomized controlled trial: Experience of a large Canadian tertiary movement disorders clinic

    J. Lam, J. Zhu, D. Meng, P. Uzelman, S. Appel-Cresswell (Vancouver, Canada)

    Objective: To report our experience of recruiting Parkinson’s disease (PD) patients with mild-to-moderate anxiety into a randomized controlled trial. Background: Anxiety is a common non-motor…
  • 2023 International Congress

    Longitudinal assessment of evolution and plasma biomarkers for depression and anxiety in Parkinson’s disease

    J. Lin, R. Ou, C. Li, Q. Wei, Y. Hou, L. Zhang, K. Liu, Q. Jiang, T. Yang, Y. Xiao, D. Pang, Y. Yu, B. Zhao, X. Chen, W. Song, J. Yang, Y. Wu, H. Shang (Chengdu, China)

    Objective: We aimed to investigatethe evolution of depression and anxietyin a large Parkinson's disease (PD) cohort and explore the related plasma biomarkers. Background: Depression and anxietyare common non-motor…
  • 2023 International Congress

    Association between type 2 diabetes mellitus with parkinson’s disease and the increase of the severity of depression and anxiety in a mexican population

    AA. Herrera Ruiz, DR. Aguila Godinez, AJ. Hernández-Medrano, MA. Ruiz Mafud, A. Abundes-Corona, A. Cervantes-Arriaga, M. Rodríguez-Violante (Mexico City, Mexico)

    Objective: To compare the severity of depression and anxiety in PwP between those with T2D and those without T2D. Background: Parkinson's disease (PD) is the…
  • 2023 International Congress

    Association between Stress and Bruxism in Egyptian University Female Students Throughout Their Final Exam Period

    MYA. Amine, U. Dakrory (Giza, Egypt)

    Objective: The Current study highlights the correlation between bruxism and stress in a group of Egyptian university students. Background: Bruxism is an involuntary contraction of…
  • 2022 International Congress

    Cognitive behavioral therapy for anxiety in Parkinson’s disease induces functional brain changes

    G. Carey, R. Lopes, A. Moonen, A. Mulders, J. de Jong, G. Kuchcinski, L. Defebvre, M. Kuijf, K. Dujardin, A. Leentjens (Lille, France)

    Objective: To identify changes in functional connectivity in the brain after cognitive behavioral therapy (CBT) for anxiety in patients with Parkinson's disease (PD). Background: CBT…
  • 2022 International Congress

    The influence of GBA and LRRK2 on mood disorders in Parkinson’s Disease

    A. Thaler, N. Omer, B. Cohen, N. Giladi, M. Kestenbaum, J. Shirvan, J. Cedarbaum, M. Gana-Weisz, O. Goldstein, A. Orr-Urtreger, A. Mirelman (Tel-Aviv, Israel)

    Objective: To assess the influence of mutations in the LRRK2 and GBA genes on mood disorders among patients with Parkinson's disease (PD) Background: Mood disorders…
  • 2022 International Congress

    Evaluation of the anxiolytic effects of naringenin in rotenone-induced rat model of Parkinson’s disease by an elevated plus maze test

    S. Madiha (Karachi, Pakistan)

    Objective: The study was designed to assess the anxiolytic effects of naringenin on rotenone-induced anxiety-like behavior, biochemical and neurochemical alterations. Background: Anxiety is a preclinical…
  • 2022 International Congress

    Relation of affective disorders and quality of life in the chronic pain of disease Parkinson’s patients

    K. Stepanchenko, A. Jidkova (Kharkiv, Ukraine)

    Objective: To study affective disorders and their impact on the quality of life in patients with PD and chronic pain syndrome. Background: Mechanisms of the…
  • 2022 International Congress

    Parkinson’s disease caregiver burden in rural India

    S. Desai, D. Desai, I. Prashnani (Anand, India)

    Objective: To assess the caregiver burden and factors determining it in patients with PD. To assess the anxiety and depression amongst caregivers. Background: Patients with…
  • « Previous Page
  • 1
  • …
  • 4
  • 5
  • 6
  • 7
  • 8
  • …
  • 19
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley